Vertex Pharmaceuticals Inc. hit a major milestone on Thursday when the U.S. Food and Drug Administration approved its ...

To support patients, Vertex provides financial assistance for fertility preservation options like freezing eggs, embryos or reproductive tissues. Last year, the HHS Office of Inspector General ...

Vertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $3.98 per share for the fourth quarter of 2024, ...

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...

Considering all of this, is Vertex a buy right now? It's true that, in spite of the general desire to replace opioids with safer options, Vertex could face headwinds if immediate cost truly is the ...

Vertex sued the HHS in July 2024 after the department’s Office of the Inspector General (OIG) decided not to issue a favorable opinion on the company’s fertility support for Casgevy patients. The gene ...

A new EMA approval has expanded the use of Vertex Pharma’s cystic fibrosis therapy Symkevi to children as young as six if they have specific gene mutations. The regulator has given a green light ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2024, and provided ...

Vertex' therapy takes the form of stem cell-derived human pancreatic islet cells, which secrete insulin in the body in response to rising blood glucose. The aim is to replace the pancreatic tissue ...